If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 21.00
Bid: 20.00
Ask: 22.00
Change: 0.00 (0.00%)
Spread: 2.00 (10.00%)
Open: 21.50
High: 21.50
Low: 19.50
Prev. Close: 21.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of NED

7 Jan 2013 07:00

RNS Number : 9111U
Angle PLC
07 January 2013
 



For immediate release

 7 January 2013

 

ANGLE plc

("ANGLE" or "the Company")

 

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

 

 

ANGLE plc (AIM: AGL), the specialist medtech company, is pleased to announce the appointment of Brian Howlett as a Non-Executive Director of the Company. The appointment is effective immediately.

 

Brian has more than 20 years' experience of building and managing medical device and diagnostic businesses, and prior to this he worked in the pharmaceutical industry.

 

Brian was CEO of AIM-quoted Lombard Medical Technologies PLC from 2005 to 2010, during which time he took the company from the development stage to product sales. He also raised a total of £49 million in equity funding in challenging financial markets.

 

From 1999 to 2005, Brian was UK Country Leader at Boston Scientific Corporation, where he was responsible for launching a number of new medical devices into the UK market. From 1987 to 1999 he was Managing Director of Cobe Laboratories Limited where he achieved significant growth in the Renal Care, Cardiovascular and Blood Component Technology (BCT) divisions.

 

Since 2010, Brian has been Non-Executive Chairman of two privately held companies, Michelson Diagnostics Limited and Vascular Flow Technologies Limited. He is also a Non-Executive Director of privately held company Accentus Limited.

 

 

ANGLE's Founder and Chief Executive, Andrew Newland, commented:

"Brian brings a wealth of business experience to ANGLE and a deep understanding of the medical diagnostic market, including product development, regulatory approvals, major corporate deals and sales strategies. We look forward to working with Brian in the continuing development of ANGLE's business."

 

 

Brian Howlett, age 68, does not currently hold shares in ANGLE. There are no further disclosures to be made in relation to Mr Howlett under Schedule 2(g) and (i) of the AIM rules.

 

 

 

 

For further information:

 

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Cenkos Securities

Stephen Keys, Adrian Hargrave (Nominated adviser)

Andy Roberts, Christian Hobart (Sales)

 

020 7397 8900

Buchanan

Mark Court, Fiona Henson, Sophie Cowles

 

020 7466 5000

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOADMGGMLVFGFZM
Date   Source Headline
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery
5th Dec 20237:00 amRNSANGLE launches Portrait+ CTC kit at SABCS
9th Nov 20237:00 amRNSLaunch of PD-L1 test to support cancer studies
9th Nov 20237:00 amRNSTrading and business update
25th Oct 20237:00 amRNSSupporting characterisation of CTCs in HNSCC
3rd Oct 20237:00 amRNSParsortix outperforms standard for DTC harvest
29th Sep 20237:00 amRNSParsortix system showcased at ACTC conference
7th Sep 20237:00 amRNSInterim Results for the period ended 30 June 2023
4th Sep 20237:00 amRNSANGLE launch of Portrait Flex assay
15th Aug 20237:00 amRNSANGLE notice of interim results
28th Jun 20234:54 pmRNSResult of 2023 Annual General Meeting
27th Jun 202312:24 pmRNSStandard form for notification of major holdings
5th Jun 20237:00 amRNSANGLE announces senior management appointments
25th May 20237:00 amRNSPharma services contract with Artios Pharma
22nd May 20237:00 amRNSBoard change - appointment of new Chairman
21st Apr 202312:04 pmRNSANGLE presentation via Investor Meet Company
21st Apr 20237:00 amRNSResults for the year ended 31 December 2022
19th Apr 20237:00 amRNSANGLE announces partnership with BioView
17th Apr 20237:00 amRNSANGLE Parsortix poster presented at AACR 2023
13th Apr 20237:00 amRNSPharma Services Contract with Crescendo Biologics
3rd Apr 20237:00 amRNSNotice of Preliminary Results and Webcast
10th Mar 20237:00 amRNSIssue of LTIP Options and Share Options
9th Mar 20233:03 pmRNSHolding(s) in Company
9th Feb 20232:44 pmRNSDirector/PDMR shareholding
19th Jan 20237:00 amRNSAppointment of Non-Executive Director
11th Jan 20235:20 pmRNSHolding(s) in Company
10th Jan 20236:20 pmRNSHolding(s) in Company
6th Jan 202311:05 amRNSSecond Price Monitoring Extn
6th Jan 202311:00 amRNSPrice Monitoring Extension
5th Jan 20239:05 amRNSSecond Price Monitoring Extn
5th Jan 20239:00 amRNSPrice Monitoring Extension
5th Jan 20237:01 amRNSAppointment of Non-Executive Director
5th Jan 20237:00 amRNSBusiness Update
12th Dec 20227:00 amRNSTwo Parsortix posters presented at SABCS
2nd Dec 20225:30 pmRNSIssue of Equity
2nd Nov 20227:00 amRNSMultiple downstream analysis techniques for CTCs
1st Nov 20224:41 pmRNSSecond Price Monitoring Extn
1st Nov 20224:35 pmRNSPrice Monitoring Extension
24th Oct 20227:00 amRNSParsortix poster presented at ISLB meeting
21st Oct 20226:15 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.